Sosei Heptares has entered a strategic multi-target partnership with Takeda Pharmaceutical Co. Ltd. to discover, develop and commercialize novel molecules, including small molecules and biologics, that modulate G protein-coupled receptor (GPCR) targets within the realm of gastrointestinal disease, but the pact could potentially expand into other therapeutic areas, Malcolm Weir, the Japanese biotech’s head of R&D, told Scrip.
Sosei Heptares Bags Second GPCR Targets Deal In A Month, With Takeda
The Japanese biotech agreed a multi-year, multi-target research collaboration and license deal with Takeda to discover and develop medicines that modulate GPCR targets, initially in GI.
More from Business
• By
European pharma leaders want to see a deal so that no tariffs are imposed on medicines – but they also want the European Union to urgently rethink its sector policies that they believe will lead to massive investment loss.
• By
The US president's most recent comments suggest tariffs on pharma are imminent and Ireland has the most to lose.
• By
Chinese biopharma companies’ alliance strategies are transitioning from immediate cash needs to more strategic management of portfolios, as MNCs continue to hunt for derisked assets.
• By
As drugmakers update investors on first quarter financial performance, uncertainty around global trade and US regulatory oversight is likely to dominate discussions.
More from Scrip
• By
As drugmakers update investors on first quarter financial performance, uncertainty around global trade and US regulatory oversight is likely to dominate discussions.
• By
Faced with Trump’s hostile tariff moves, the UK aims to speed up clinical trial start times to support its pharma sector and invest £600m in a new health data research service.
• By
The biotech has rejected a takeover bid from Nordic Capital but a sale to private equity could be a solution to the public market's continued reluctance to adequately value PureTech’s hub-and-spoke business model.